Genocea Biosciences, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 74
- Market Cap
- -
- Website
- http://www.genocea.com
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- Genocea Biosciences, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT04596033
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2022-04-19
- Lead Sponsor
- Genocea Biosciences, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03633110
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸John Wayne Cancer Institute - Providence Saint John's Health Center, Santa Monica, California, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
- Conditions
- Interventions
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- Genocea Biosciences, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT03146403
- Locations
- 🇺🇸
UNC Health, Chapel Hill, North Carolina, United States
🇺🇸Tekton Research, Austin, Texas, United States
🇺🇸University of Alabama Birmingham, Birmingham, Alabama, United States
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
- Conditions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- Genocea Biosciences, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT02910284
- Locations
- 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Quest Clinical Research, San Francisco, California, United States
🇺🇸University of Alabama - Birmingham, Birmingham, Alabama, United States
Evaluating New Formulation of Therapeutic HSV-2 Vaccine
- Conditions
- Interventions
- First Posted Date
- 2015-08-04
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- Genocea Biosciences, Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT02515175
- Locations
- 🇺🇸
The Fenway Institute, Boston, Massachusetts, United States
🇺🇸University of Washington, Seattle, Washington, United States
🇺🇸Medical Center for Clinical Research, San Diego, California, United States
Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- Genocea Biosciences, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT02300142
- Locations
- 🇺🇸
Tekton Research, Austin, Texas, United States
🇺🇸Center for Clinical Studies, Houston, Texas, United States
🇺🇸Center for Clinical Studies - Clear Lake/Webster, Webster, Texas, United States
Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2018-04-06
- Lead Sponsor
- Genocea Biosciences, Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT02116998
- Locations
- 🇬🇧
Royal Liverpool University Hospital, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- Genocea Biosciences, Inc.
- Target Recruit Count
- 310
- Registration Number
- NCT02114060
- Locations
- 🇺🇸
University of Illinois Department of Medicine, Chicago, Illinois, United States
🇺🇸Center for Clinical Studies, Houston, Texas, United States
🇺🇸UW Virology Research Clinic, Seattle, Washington, United States
Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2015-12-11
- Lead Sponsor
- Genocea Biosciences, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT01995617
- Locations
- 🇺🇸
Prism Research, Saint Paul, Minnesota, United States
Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine
- Conditions
- Interventions
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2018-06-01
- Lead Sponsor
- Genocea Biosciences, Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT01667341
- Locations
- 🇺🇸
Center for Clinical Studies - Houston, Houston, Texas, United States
🇺🇸UW Virology Research Clinic, Seattle, Washington, United States
🇺🇸University of Alabama Vaccine Research Unit, Birmingham, Alabama, United States